Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05242367
Other study ID # MS003
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 13, 2023
Est. completion date October 2024

Study information

Verified date May 2024
Source Neurovalens Ltd.
Contact Joe Reel
Phone 2890991835
Email joe.reel@neurovalens.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Trial title: A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of PTSD The aim of this study: To better evaluate the efficacy of non-invasive electrical vestibular nerve stimulation (VeNS) as a method of treating PTSD, as compared to a sham control. Allocation: Randomized to either active device or control device usage. Endpoint classification: Efficacy Study Intervention Model: Parallel Assignment in 1:1 active to control allocation Sample size: The aim is to recruit a total of up to 300 participants. The study will last 12 weeks in total for each subject.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date October 2024
Est. primary completion date October 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years to 80 Years
Eligibility Inclusion Criteria: - Signed informed consent - Diagnosed PTSD by a medical practitioner - Post-Traumatic Checklist (PCL-5) score or 31 or above - Eligibility confirmed via the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) - Male or female, age = 22 years and = 80 years at the time of signing informed consent - Ability and willingness to complete all study visits and procedures, including completion of mental health questionnaires - Ability and willingness to adhere to 30 minutes usage of the device daily for the duration of the trial - Agreement not to start any new PTSD, mental health, or insomnia medications for the duration of the trial and/or to inform the study team if intending on starting any new PTSD, mental health, or insomnia medications - Agreement not to change any PTSD specific treatments for the duration of the trial e.g cognitive processing therapy - Agreement not to undergo any significant lifestyle changes that may affect sleep (e.g. excessive exercise, sleep interventions etc.) for the duration of the trial - Agreement not to use sleep trackers (e.g. Fitbit) for the duration of the trial - Agreement not to travel across different time zones for the duration of the trial - Access to Wi-Fi (for app to be able to upload usage data) - Access to computer, laptop, iPad or tablet (to conduct remote study visits and complete study questionnaires remotely) - Screening review by PTSD physician (study PI) - Willingness to download and use a video platform (e.g Zoom) to conduct remote study visits - Willingness to engage weekly with your Clinical Trial Mentor (CTM) Exclusion Criteria: - History of skin breakdown, eczema, or other dermatological condition (e.g., psoriasis) affecting the skin behind the ears - History of severe tinnitus or vertigo - History or presence of malignancy within the last year - Use of beta-blockers within 1 month of starting the study - History of chronic viral infection that causes vestibular neuropathy (e.g., hepatitis or HIV) - Use of antihistamines - A history of stroke or severe head injury as defined by a head injury that required a craniotomy or endotracheal intubation (in case this damaged the neurological pathways involved in vestibular stimulation) - Taking H2-receptor antagonist medication - Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.) - Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method - Diagnosis of epilepsy - Diagnosis of active migraines - Previous use of Modius device - Participation in other research studies sponsored by Neurovalens - Participation in any other PTSD studies - Not fluent in English language - Have a member of the same household who is currently participating in this study - Failure to agree to use of device daily during study participation - Any other medical condition, or medication use, that in the opinion of the PI is likely to make the subject refractory to VeNS.

Study Design


Intervention

Device:
Modius Spero active device
Battery powered non-invasive neurostimulation device
Sham device
Placebo comparator sham device (no active stimulation)

Locations

Country Name City State
United States VA San Diego Healthcare System San Diego California

Sponsors (3)

Lead Sponsor Collaborator
Neurovalens Ltd. Clinical Trial Mentors, University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Posttraumatic Stress Disorder Checklist PCL-5 score To evaluate the effect of the Modius Sleep device, relative to control group, on the symptoms of PTSD, quantified by change in the PCL-5 Score. 12 weeks
Secondary 36-Item Short Form Survey (SF-36) score To evaluate the effect of the Modius Spero device, relative to control group, on quality of life quantified by change in SF-36 score. 12 weeks
Secondary Generalised Anxiety Disorder (GAD-7) score To evaluate the effect of the Modius Spero device, relative to control group, on anxiety, quantified by change in the GAD-7 score. GAD-7 is a self-report rating scale assessing the severity of anxiety (range 0-21), with higher score indicating more severe anxiety. 12 weeks
Secondary Insomnia Severity Index (ISI) score To evaluate the effect of the Modius Spero device, relative to control group, on participants with insomnia. ISI is a self-report rating scale assessing the severity of insomnia symptoms (range 0-28) with higher scores indicating a more severe insomnia. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Recruiting NCT05934162 - Efficacy of Internet-delivered Cognitive-behavior Therapy for PTSD N/A
Recruiting NCT05934175 - Intensive Treatment Versus Standard Weekly Prolonged Exposure for Adults With Post-Traumatic Stress Disorder N/A
Completed NCT04460014 - Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT N/A
Completed NCT05877807 - Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
Active, not recruiting NCT05992649 - The Effect of Aquatic Physiotherapy on Veterans Suffering From PTSD - a 40-week Pilotproject N/A
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Not yet recruiting NCT05331534 - Effect of Attentional Therapy on Post-traumatic Stress Disorder N/A
Not yet recruiting NCT03649607 - Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black N/A
Not yet recruiting NCT04076215 - Biochemical and Physiological Response to Stressogenic Stimuli N/A
Not yet recruiting NCT02545192 - A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments Phase 1
Completed NCT02329418 - Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit N/A
Active, not recruiting NCT00978484 - A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder Phase 3
Completed NCT00760734 - Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD) Phase 1
Completed NCT03278171 - Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit
Recruiting NCT05874362 - People Bereaved by Violent Death : Negative Event Biases and Temporal Perception N/A
Terminated NCT03898843 - Assisted Animal Therapy: ReAnimal N/A
Recruiting NCT04747379 - Psychological Effect of Explicit Recall After Sedation (PEERS)
Completed NCT03248167 - Cannabidiol as a Treatment for AUD Comorbid With PTSD Phase 1/Phase 2